Related Experiment Videos

Selective expression of inducible nitric oxide synthase in human prostate carcinoma

T Klotz1, W Bloch, C Volberg

  • 1Department of Urology, University of Cologne, Germany.

Cancer
|May 20, 1998
PubMed
Abstract

Insights

Inducible nitric oxide synthase (iNOS) is highly expressed in prostate carcinoma tissue but not in benign tissue. This suggests iNOS may serve as a specific biomarker for prostate cancer detection.

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Nitric oxide (NO) synthesized by inducible nitric oxide synthase (iNOS) is implicated in tumor growth, angiogenesis, and immune modulation.
  • The role of iNOS in prostate carcinoma and its expression in tumor tissue were previously undetermined.

Purpose of the Study:

  • To investigate the expression of iNOS in prostate carcinoma tissue.
  • To determine if iNOS can serve as a specific marker for prostate cancer.

Main Methods:

  • Immunohistochemical analysis of iNOS expression in prostate carcinoma tissue samples (n=16).
  • Comparison with tissue specimens from patients with benign prostatic hyperplasia (n=10).

Main Results:

  • All prostate carcinoma tissue sections exhibited positive iNOS immunostaining, particularly in malignant epithelial cells.
  • Macrophages in the tumor microenvironment also showed positive iNOS staining.
  • Benign hyperplasia tissue and associated cells showed no iNOS expression.

Conclusions:

  • Prostate carcinoma tissue demonstrates significantly higher iNOS content compared to benign tissue.
  • Epithelial iNOS expression is proposed as a specific immunohistochemical marker for prostate carcinoma.
  • iNOS-derived NO likely plays a multifaceted role in prostate cancer development.

Related Concept Videos